Compare REA & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REA | SLN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | | United Kingdom |
| Employees | N/A | 88 |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.9M | 300.9M |
| IPO Year | 2026 | N/A |
| Metric | REA | SLN |
|---|---|---|
| Price | $11.75 | $9.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 150.8K | ★ 628.4K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.80 | $4.19 |
| 52 Week High | $17.84 | $11.06 |
| Indicator | REA | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 16.75 | 62.98 |
| Support Level | N/A | $5.87 |
| Resistance Level | $16.18 | N/A |
| Average True Range (ATR) | 1.41 | 0.87 |
| MACD | -0.44 | 0.14 |
| Stochastic Oscillator | 6.16 | 73.13 |
Rare Earths Americas Inc is an exploration stage company focused on advancing projects related to rare earth minerals. Its activities include evaluating mineralization and assessing the characteristics and economic potential of its assets. Its portfolio includes the Shiloh Project in Georgia, United States; the Alpha Project in Bahia, Brazil; and the Constellation Project in Minas Gerais, Brazil. It also holds additional early-stage exploration projects, including the Homer Project in Goiás, Brazil, and the Liberty Peak Project in Georgia, United States. The company has two reportable segments due to their geographical location: United States Mining Operations and Brazil Mining Operations.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.